norfloxacin has been researched along with Leukemia in 15 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of a combination regimen using norfloxacin (NFLX) and amphotericin B (AMPH-B) for prevention of infections in patients with acute leukemia being treated by remission-induction chemotherapy in a randomized, controlled trial was studied." | 9.07 | Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. ( Dan, K; Nomura, T; Yamada, T, 1993) |
| "Seventy-three patients mainly receiving consolidation therapy for acute leukemia or autologous bone marrow transplantation were studied in a randomized trial comparing nystatin with norfloxacin (800 mg) given orally QID, for prevention of infection." | 9.07 | [A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study]. ( Hattori, M; Maseki, N; Sampi, K, 1992) |
| "A total of 63 neutropenic patients receiving cytotoxic therapy for acute leukemia were randomly allocated to receive norfloxacin (400 mg every 12 hours) or cotrimoxazole (160/800 mg every 12 hours) to prevent bacterial infection." | 9.06 | Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. ( Bow, EJ; Louie, TJ; Rayner, E, 1988) |
| "Aerobic gram negative bacterial infections occur commonly in patients with acute leukemia undergoing intensive chemotherapy-induced bone marrow aplasia, and often arise from the gastrointestinal (GI) tract." | 6.66 | Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1986) |
| "In a randomized study comparing cotrimoxazole plus colistin with ciprofloxacin, each in combination with nonabsorbable antimycotics, the incidence of major infections in terms of septicemias and pneumonias as well as of minor infections and episodes of unexplained fever (FUO) was higher in patients treated with ciprofloxacin." | 6.16 | Prevention of infection in acute leukemia. ( Daenen, S; de Pauw, BE; de Vries-Hospers, HG; Dekker, AW; Donnelly, JP; Gaus, W; Haralambie, E; Kern, W; Konrad, H; Maschmeyer, G, 1990) |
| "The effect of a combination regimen using norfloxacin (NFLX) and amphotericin B (AMPH-B) for prevention of infections in patients with acute leukemia being treated by remission-induction chemotherapy in a randomized, controlled trial was studied." | 5.07 | Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. ( Dan, K; Nomura, T; Yamada, T, 1993) |
| "Seventy-three patients mainly receiving consolidation therapy for acute leukemia or autologous bone marrow transplantation were studied in a randomized trial comparing nystatin with norfloxacin (800 mg) given orally QID, for prevention of infection." | 5.07 | [A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study]. ( Hattori, M; Maseki, N; Sampi, K, 1992) |
| "More patients receiving ciprofloxacin did not develop fever during neutropenia and did not receive antibiotics (34%) compared with those receiving norfloxacin (25%) (P = 0." | 5.07 | Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. ( , 1991) |
| " The treatment of 37 initial febrile episodes (12 cases of septicemia, 7 infectious sites and 38 cases of fever of unknown origin) in 33 neutropenic patients (PMN leucocytes less than 500/mm3) using the combination of a third generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacin) resulted in an 86% immediate success rate (32 cases/37)." | 5.06 | [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)]. ( Bielefeld, P; Caillot, D; Guy, H; Kazmierczak, A; Portier, H; Solary, E, 1987) |
| "A total of 63 neutropenic patients receiving cytotoxic therapy for acute leukemia were randomly allocated to receive norfloxacin (400 mg every 12 hours) or cotrimoxazole (160/800 mg every 12 hours) to prevent bacterial infection." | 5.06 | Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis. ( Bow, EJ; Louie, TJ; Rayner, E, 1988) |
| "Norfloxacin has been compared to placebo (136 patients), sulfamethoxazole plus trimethoprim (SXT, 72 patients) and oral vancomycin plus colistin (V/C, 61 patients) for the prevention of alimentary tract-associated infections during and after induction chemotherapy." | 2.66 | The tolerability profile of prophylactic norfloxacin in neutropenic patients. ( Corrado, ML; Hesney, M; Struble, WE, 1988) |
| "Aerobic gram negative bacterial infections occur commonly in patients with acute leukemia undergoing intensive chemotherapy-induced bone marrow aplasia, and often arise from the gastrointestinal (GI) tract." | 2.66 | Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (53.33) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liso, V | 1 |
| Specchia, G | 1 |
| Pavone, V | 1 |
| Pansini, N | 1 |
| Capalbo, S | 1 |
| Ostuni, A | 1 |
| Mastria, A | 1 |
| Colucci, A | 1 |
| Costantino, G | 1 |
| Yamada, T | 1 |
| Dan, K | 1 |
| Nomura, T | 1 |
| Aricò, M | 1 |
| Bossi, G | 1 |
| Caselli, D | 1 |
| Cosi, G | 1 |
| Villa, A | 1 |
| Beluffi, G | 1 |
| Genovese, E | 1 |
| Carratala, J | 1 |
| Fernandez-Sevilla, A | 1 |
| Tubau, F | 1 |
| Dominguez, MA | 1 |
| Gudiol, F | 1 |
| Sampi, K | 1 |
| Maseki, N | 1 |
| Hattori, M | 1 |
| De Beule, F | 1 |
| Bercy, P | 1 |
| Ferrant, A | 1 |
| Maschmeyer, G | 1 |
| Daenen, S | 1 |
| de Pauw, BE | 1 |
| de Vries-Hospers, HG | 1 |
| Dekker, AW | 1 |
| Donnelly, JP | 1 |
| Gaus, W | 1 |
| Haralambie, E | 1 |
| Kern, W | 1 |
| Konrad, H | 1 |
| Del Favero, A | 1 |
| Martino, P | 2 |
| Bucaneve, G | 1 |
| Micozzi, A | 1 |
| D'Antonio, D | 1 |
| Minetti, B | 1 |
| Ricci, P | 1 |
| Landonio, G | 1 |
| Montillo, M | 1 |
| Malleo, C | 1 |
| Giuliano, M | 1 |
| Pantosti, A | 1 |
| Gentile, G | 1 |
| Venditti, M | 1 |
| Arcese, W | 1 |
| Nemet, D | 1 |
| Kalenic, S | 1 |
| Badanjak, A | 1 |
| Bogdanic, V | 1 |
| Davila, N | 1 |
| Francetić, I | 1 |
| Labar, B | 1 |
| Guy, H | 1 |
| Caillot, D | 1 |
| Solary, E | 1 |
| Bielefeld, P | 1 |
| Portier, H | 1 |
| Kazmierczak, A | 1 |
| Corrado, ML | 1 |
| Struble, WE | 1 |
| Hesney, M | 1 |
| Bow, EJ | 1 |
| Rayner, E | 1 |
| Louie, TJ | 1 |
| Karp, JE | 1 |
| Merz, WG | 1 |
| Hendricksen, C | 1 |
| Laughon, B | 1 |
| Redden, T | 1 |
| Bamberger, BJ | 1 |
| Bartlett, JG | 1 |
| Saral, R | 1 |
| Burke, PJ | 1 |
1 review available for norfloxacin and Leukemia
| Article | Year |
|---|---|
Prevention of infection in acute leukemia.
Topics: Acute Disease; Anti-Bacterial Agents; Ciprofloxacin; Colistin; Drug Therapy, Combination; Humans; In | 1990 |
11 trials available for norfloxacin and Leukemia
| Article | Year |
|---|---|
Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B.
Topics: Administration, Oral; Adult; Amphotericin B; Antineoplastic Agents; Bacterial Infections; Drug Combi | 1993 |
[A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study].
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Bacterial Infections; Bone Marrow Transplant | 1992 |
Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Fever; | 1991 |
Prevention of infection in acute leukemia.
Topics: Acute Disease; Anti-Bacterial Agents; Ciprofloxacin; Colistin; Drug Therapy, Combination; Humans; In | 1990 |
[Prophylaxis using quinolones in neutropenic patients. Preliminary results of a cooperative study by the Grupo Italiano Malattie Ematologiche maligne dell'adulto (GIMEMEA)].
Topics: Agranulocytosis; Anti-Bacterial Agents; Bacterial Infections; Bone Marrow Transplantation; Ciproflox | 1989 |
Effects on oral and intestinal microfloras of norfloxacin and pefloxacin for selective decontamination in bone marrow transplant patients.
Topics: Adult; Bone Marrow Transplantation; Drug Resistance, Microbial; Feces; Female; Humans; Immunosuppres | 1989 |
Prevention of gram-negative bacterial infection in granulocytopenic patients: a randomized study comparing oral norfloxacin with gentamycin.
Topics: Administration, Oral; Adolescent; Adult; Agranulocytosis; Bacterial Infections; Gentamicins; Gram-Ne | 1989 |
[Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)].
Topics: Agranulocytosis; Anti-Infective Agents; Cefotaxime; Ceftazidime; Drug Evaluation; Drug Therapy, Comb | 1987 |
The tolerability profile of prophylactic norfloxacin in neutropenic patients.
Topics: Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Colistin; Diarrhea; Gastrointestina | 1988 |
Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis.
Topics: Acute Disease; Adult; Antineoplastic Agents; Bacterial Infections; Clinical Trials as Topic; Drug Co | 1988 |
Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Agranulocytosis; Bacterial Infections; Clinical Tr | 1986 |
4 other studies available for norfloxacin and Leukemia
| Article | Year |
|---|---|
Prophylactic administration of oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemias.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Agents | 1989 |
Long-term magnetic resonance survey of cartilage damage in leukemic children treated with fluoroquinolones.
Topics: Anti-Infective Agents; Cartilage; Cartilage Diseases; Child; Female; Follow-Up Studies; Humans; Leuk | 1995 |
Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; DNA, Bacterial; Drug Resistance, Micr | 1996 |
The effectiveness of a preventive regimen on the periodontal health of patients undergoing chemotherapy for leukemia and lymphoma.
Topics: Acyclovir; Amphotericin B; Ceftazidime; Chlorhexidine; Dental Plaque Index; Fluconazole; Humans; Imm | 1991 |